# Prime Medicine, Inc.: Phase 2 study in Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease (54 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Prime Medicine, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency |
| NCT ID | NCT07887347 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Alpha-1 Antitrypsin Deficiency; Alpha-1 Antitrypsin Deficiency-associated Lung Disease; Alpha-1 Antitrypsin Deficiency (AATD); AATD |
| Intervention types | drug |
| Target enrollment | 54 |
| Posted | 2026-10-21 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07887347). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.